secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001390478-26-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS reports FY2025 net loss $26.9M ($0.25/shr); cash $71.8M; Phase 3 REGAL AML trial approaching final analysis
--------------------------------------------------------------------------------

- FY2025 net loss $26.9M ($0.25/shr) vs $30.9M ($0.50/shr) in FY2024; cash $71.8M at Dec 31, 2025.
- Received additional $42.6M from warrant exercises in Q1 2026, strengthening balance sheet.
- Phase 3 REGAL trial of GPS in AML nearing final analysis at 80 events; 72 events as of Dec 26, 2025.
- Phase 2 SLS009 in r/r AML showed 46% ORR; expansion into newly diagnosed AML underway, first patient dosed.
- European collaboration with IMPACT-AML to study SLS009 in ~40 newly diagnosed AML patients; enrollment expected Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/0001390478-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/sls-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001390478-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer